KSI-301
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-proliferative Diabetic Retinopathy
Conditions
Non-proliferative Diabetic Retinopathy
Trial Timeline
Sep 7, 2021 → Aug 31, 2023
NCT ID
NCT05066230About KSI-301
KSI-301 is a phase 3 stage product being developed by Kodiak Sciences for Non-proliferative Diabetic Retinopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05066230. Target conditions include Non-proliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05066230 | Phase 3 | Terminated |
| NCT03790852 | Phase 1 | Terminated |
Competing Products
2 competing products in Non-proliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | Ocular Therapeutix | Phase 3 | 72 |
| OTX-TKI + Sham | Ocular Therapeutix | Phase 1 | 28 |